Cambridge Healthtech Institute’s 5th Annual

Protein Degraders and Molecular Glues

Part 1: Covalent Chemistries, New Ligases for Induced Proximity

September 26-27, 2023

Part 2: Design and Optimization of Novel Degrader Modalities

September 27-28, 2023

A new generation of molecules are being developed to disrupt protein-protein interactions and to hijack the cell’s natural machinery for targeted protein degradation. Proteolysis-targeting chimeras (PROTACs), molecular glues, and other modalities are utilizing the ubiquitin-proteasome, lysosome, and autophagy systems to seek out previously “undruggable” targets for therapeutic intervention. Cambridge Healthtech Institute’s two-part conference on Protein Degraders and Molecular Glues brings together experts from industry and academia to discuss targeted protein degradation as a viable therapeutic approach.

Who should attend: Scientist in Oncology, Molecular and Cellular Biology, Discovery Biology, Target Discovery, Medicinal Chemistry, Drug Design, Discovery Chemistry, Lead Discovery, Chemical Biology, Proteomics, Computational Biology, Computational Chemistry, Assay Development and Screening.

Part 1:

Part 1 focuses on emerging assays and screening strategies for new ligases and neosubstrates for targeted degradation. The use of covalent chemistry for inducing chemical proximity and use of AI/ML predictions and modeling to enable targeted protein degradation will also be discussed.

Coverage will include, but is not limited to:

Emerging tools and assays to identify novel ligases and drug targets
Innovative chemistries and screening for induced proximity
Case studies highlighting chemoproteomics and covalent ligands for protein degradation
Structural and mechanistic studies for understanding recruitment and degradation pathways
AI/ML tools for designing and predicting induced proximity and degradation

Part 2:

Part 2 will discuss the design and optimization of new monovalent and heterobifunctional degraders. Challenges that exist in terms of specificity, stability, biodistribution, and penetration of these degrader molecules for better in vitro to in vivo translation will be discussed.

Coverage will include, but is not limited to:

Design, characterization, and optimization of novel PROTACs and molecular glues
New degrader molecules for new ligases
Understanding challenges around degrader efficacy and tissue specificity
Tackling issues surrounding stability, biodistribution, oral availability, and more
Pursuing previously undruggable targets: KRAS, transcription factors, and more
Understanding in vitro to in vivo translation
Updates on novel degradation strategies being pursued

The deadline for priority consideration is March 17, 2023.

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

Opportunities for Participation: